Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 USD | -6.23% | -12.33% | -7.25% |
Mar. 27 | Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating | MT |
Mar. 27 | Wedbush Adjusts bluebird bio's PT to $1.72 From $1.68, Maintains Neutral Rating | MT |
Chart calendar bluebird bio, Inc.
Upcoming events on bluebird bio, Inc.
Past events on bluebird bio, Inc.
2024-03-26 08:00 am | Q4 2023 Earnings Call |
2024-03-26 07:00 am | Q4 2023 Earnings Release |
2024-01-09 01:30 pm | JPMorgan Healthcare Conference |
2023-12-11 07:30 pm | American Society of Hematology Meeting - Oral No :#1051 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Poster No:#2480 |
2023-12-09 08:30 pm | American Society of Hematology Meeting - Poster No:#1102 |
2023-12-08 04:15 pm | FDA Approved Call |
2023-11-07 08:00 am | Q3 2023 Earnings Call |
2023-11-07 07:00 am | Q3 2023 Earnings Release |
2023-09-12 02:00 pm | Baird Global Healthcare Conference |
2023-09-11 12:15 pm | Morgan Stanley Global Healthcare Conference |
2023-08-08 08:00 am | Q2 2023 Earnings Call |
2023-08-08 07:00 am | Q2 2023 Earnings Release |
2023-06-16 08:30 am | Annual General Meeting |
2023-06-12 07:40 pm | Goldman Sachs Global Healthcare Conference |
2023-05-11 11:15 am | Bank of America Healthcare Conference |
2023-05-09 07:00 am | Q1 2023 Earnings Release |
2023-03-29 08:00 am | Q4 2022 Earnings Call |
2023-03-29 07:00 am | Q4 2022 Earnings Release |
2023-01-12 10:30 am | JP Morgan Healthcare Conference |
Past dividends on bluebird bio, Inc.
2021-11-04 | 0 |
Annual results
Fiscal Period | December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 54,6 43,0 26.85% | 44,7 43,4 2.92% | 251 259 -3.22% | 3,66 48,0 -92.37% | 3,60 40,9 -91.2% | 38,1 |
EBITDA Million USD | Released Forecast Spread | -555 -559 0.68% | -797 -766 -4.12% | -604 -608 0.72% | -571 -791 27.76% | -379 -324 -16.94% | -281 |
EBIT Million USD | Released Forecast Spread | -572 -573 0.09% | -815 -804 -1.32% | -623 -624 0.18% | -591 -811 27.18% | -384 -363 -5.96% | -283 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -555 -562 1.1% | -790 -782 -1.03% | -618 -623 0.77% | -562 -759 25.86% | -266 -319 16.37% | -199 |
Net income Million USD | Released Forecast Spread | -556 -562 1.07% | -790 -781 -1.04% | -619 -624 0.79% | -819 -762 -7.49% | -267 -332 19.71% | -199 |
EPS USD | Released Forecast Spread | -10,7 -10,8 1.01% | -14,3 -14,1 -1.78% | -9,95 -9,94 -0.13% | -11,9 -10,8 -10.32% | -3,39 -3,94 14.02% | -1,72 |
Announcement Date | 21/02/19 | 18/02/20 | 23/02/21 | 04/03/22 | 29/03/23 | - |
Quarterly results
Fiscal Period | December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 22,7 41,5 -45.34% | 1,61 5,08 -68.41% | 1,95 0,17 1066.98% | 1,52 0,71 115.02% | 0,07 1,07 -93.39% | 0,06 15,4 -99.6% | 2,38 27,0 -91.17% | 6,89 11,3 -38.77% | 12,4 13,4 -7.57% | 14,7 | 19,2 | 21,8 | 31,9 | 51,7 |
EBITDA Million USD | Released Forecast Spread | -191 -176 -8.51% | -133 -116 -14.63% | -119 -87,7 -36.08% | -99,4 -90,6 -9.77% | -85,1 -78,0 -9.09% | -75,3 -33,5 -124.8% | -83,4 -28,5 -192.67% | -84,3 -79,1 -6.57% | -83,7 -81,9 -2.1% | -92,7 | ||||
EBIT Million USD | Released Forecast Spread | -197 -176 -11.59% | -136 -123 -9.97% | -120 -109 -10.72% | -101 -93,7 -7.5% | -86,5 -81,5 -6.09% | -76,6 -81,7 6.23% | -84,5 -36,3 -132.8% | -85,3 -76,1 -12.08% | -84,7 -81,1 -4.54% | -87,0 | -75,7 | -71,8 | -65,3 | -53,2 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -217 -179 -20.87% | -132 -127 -4.39% | -122 -108 -13.13% | -100 -99,8 -0.37% | -76,5 -84,9 9.89% | 32,3 -81,2 139.83% | 21,2 -3,97 634.53% | -73,0 -74,1 1.51% | -71,7 -77,4 7.31% | -78,8 | -70,0 | -66,4 | -59,7 | -46,3 |
Net income Million USD | Released Forecast Spread | -217 -179 -21.23% | -155 -121 -28.45% | -122 -103 -18.99% | -100 -95,5 -4.83% | -76,5 -86,3 11.34% | 32,2 -86,1 137.42% | 21,2 -23,5 190.25% | -72,9 -73,8 1.15% | -71,7 -75,8 5.32% | -82,8 | -67,9 | -65,9 | -59,0 | -44,8 |
EPS USD | Released Forecast Spread | -3,16 -2,52 -25.57% | -2,14 -1,76 -21.83% | -1,66 -1,36 -22.26% | -1,36 -1,29 -5.7% | -0,94 -1,18 20.34% | 0,38 -0,20 288.95% | 0,21 -0,31 167.57% | -0,67 -0,71 5.03% | -0,66 -0,67 2.2% | -0,65 | -0,47 | -0,44 | -0,37 | -0,30 |
Announcement Date | 05/11/21 | 04/03/22 | 09/05/22 | 04/08/22 | 07/11/22 | 29/03/23 | 09/05/23 | 08/08/23 | 07/11/23 | - | - | - | - | - |
Past sector events for bluebird bio, Inc.
Today | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
2024-03-28 04:02 pm | IMMUNOME, INC.: Q4 2023 Earnings Release |
2024-03-28 07:00 am | INVIVYD, INC.: Q4 2023 Earnings Release |
2024-03-27 | BEIGENE, LTD.: Q4 2023 Earnings Release |
2024-03-27 | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
2024-03-27 04:01 pm | CELCUITY INC.: Q4 2023 Earnings Release |
2024-03-27 07:00 am | ALTIMMUNE, INC.: Q4 2023 Earnings Release |
2024-03-26 | LEPU BIOPHARMA CO., LTD.: Q4 2023 Earnings Release |
2024-03-26 | REMEGEN CO., LTD.: Q4 2023 Earnings Release |
2024-03-26 | PHILOGEN S.P.A.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock
- Equities
- Stock bluebird bio, Inc. - Nasdaq
- Calendar bluebird bio, Inc.